Menopausal status influences long-term benefit from anti-hormonal treatment, study shows

Today, women with estrogen-sensitive breast cancer receive anti-hormonal therapy. Researchers now show that postmenopausal women with low-risk tumors have a long-term benefit for at least 20 years, while the benefit was more short-term for younger women with similar tumor characteristics who had not yet gone through the menopause. The results are reported in the Journal of the National Cancer Institute.

In Sweden, 9,000 women are diagnosed with breast cancer each year, with hormone-sensitive breast cancer accounting for about 75% of women diagnosed with the disease. In patients with hormone-sensitive breast cancer, tumor growth is mainly driven by estrogen and patients are therefore treated with estrogen-suppressing drugs, often tamoxifen.

However, anti-hormonal treatment reduces quality of life and the question has been how the long-term benefit against recurrence looks like. About a third of women diagnosed with breast cancer are younger and have not yet undergone the menopause, i.e. they are premenopausal, and are known to have an increased risk of recurrence.

“Younger women generally have a higher risk of recurrence than older postmenopausal women, but most studies on anti-hormonal therapy have mainly included postmenopausal women. We therefore wanted to compare the long-term benefit from the treatment in both groups,” says Linda Lindström, associate professor and research group leader at the Department of Oncology-Pathology, Karolinska Institutet, who led the study.

The study included more than 1,200 women diagnosed with hormone-dependent breast cancer between 1976 and 1997, of which almost 400 were premenopausal. At the start of the study, it was not known whether anti-hormonal treatment was beneficial and therefore, women were randomized to treatment with tamoxifen for at least two years or no anti-hormonal treatment, i.e. the control group.

The outcome of interest was breast cancer metastasis or distant recurrence and today there is follow-up data for more than 20 years after initial diagnosis.

“From the regional breast cancer registry, we have an almost complete follow-up on all patients and this together with a control group who did not receive anti-hormonal treatment makes the study unique. There is also complete data on whether the women were pre- or post-menopausal at diagnosis, which is otherwise often estimated based on age,” says Annelie Johansson, researcher at the same department and the study’s first author.

The women’s tumors were classified as low or high risk based on the clinically used markers. Low risk tumor characteristics were defined as a tumor size of two centimeters in diameter or less, no lymph node spread, low tumor grade, being positive for the progesterone receptor, and a low genomic risk, which was determined by a molecular signature that measures the expression of 70 different genes.

Women with high-risk tumors had less benefit against distant recurrence, whether they had gone through menopause or not. Women with low-risk tumors after menopause had a long-term benefit of 20 years or more. For younger women who had not gone through menopause at diagnosis, a long-term benefit could not be predicted using the clinically used markers. Therefore, new markers are needed, the researchers say.

“We need to work further to understand which tumor characteristics influence the long-term risk of recurrence and benefit in younger patients. We want patients to benefit from their treatment for as long as the risk of recurrence is elevated,” says Lindström.

In the next step, the researchers want to be able to link more complex tumor characteristics to the long-term risk and benefit of anti-hormonal therapy, in order to individualize the treatment to the patients who benefit from it.

“For example, we plan to perform multi-protein analyses and use machine learning for image analysis of breast cancer tumors to understand more about tumor heterogeneity—i.e. differences between and within tumors—and how it affects risk and treatment benefit,” says Lindström.

Today, women with estrogen-sensitive breast cancer receive anti-hormonal therapy. Researchers now show that postmenopausal women with low-risk tumors have a long-term benefit for at least 20 years, while the benefit was more short-term for younger women with similar tumor characteristics who had not yet gone through the menopause. The results are reported in the Journal of the National Cancer Institute.

In Sweden, 9,000 women are diagnosed with breast cancer each year, with hormone-sensitive breast cancer accounting for about 75% of women diagnosed with the disease. In patients with hormone-sensitive breast cancer, tumor growth is mainly driven by estrogen and patients are therefore treated with estrogen-suppressing drugs, often tamoxifen.

However, anti-hormonal treatment reduces quality of life and the question has been how the long-term benefit against recurrence looks like. About a third of women diagnosed with breast cancer are younger and have not yet undergone the menopause, i.e. they are premenopausal, and are known to have an increased risk of recurrence.

“Younger women generally have a higher risk of recurrence than older postmenopausal women, but most studies on anti-hormonal therapy have mainly included postmenopausal women. We therefore wanted to compare the long-term benefit from the treatment in both groups,” says Linda Lindström, associate professor and research group leader at the Department of Oncology-Pathology, Karolinska Institutet, who led the study.

The study included more than 1,200 women diagnosed with hormone-dependent breast cancer between 1976 and 1997, of which almost 400 were premenopausal. At the start of the study, it was not known whether anti-hormonal treatment was beneficial and therefore, women were randomized to treatment with tamoxifen for at least two years or no anti-hormonal treatment, i.e. the control group.

The outcome of interest was breast cancer metastasis or distant recurrence and today there is follow-up data for more than 20 years after initial diagnosis.

“From the regional breast cancer registry, we have an almost complete follow-up on all patients and this together with a control group who did not receive anti-hormonal treatment makes the study unique. There is also complete data on whether the women were pre- or post-menopausal at diagnosis, which is otherwise often estimated based on age,” says Annelie Johansson, researcher at the same department and the study’s first author.

The women’s tumors were classified as low or high risk based on the clinically used markers. Low risk tumor characteristics were defined as a tumor size of two centimeters in diameter or less, no lymph node spread, low tumor grade, being positive for the progesterone receptor, and a low genomic risk, which was determined by a molecular signature that measures the expression of 70 different genes.

Women with high-risk tumors had less benefit against distant recurrence, whether they had gone through menopause or not. Women with low-risk tumors after menopause had a long-term benefit of 20 years or more. For younger women who had not gone through menopause at diagnosis, a long-term benefit could not be predicted using the clinically used markers. Therefore, new markers are needed, the researchers say.

“We need to work further to understand which tumor characteristics influence the long-term risk of recurrence and benefit in younger patients. We want patients to benefit from their treatment for as long as the risk of recurrence is elevated,” says Lindström.

In the next step, the researchers want to be able to link more complex tumor characteristics to the long-term risk and benefit of anti-hormonal therapy, in order to individualize the treatment to the patients who benefit from it.

“For example, we plan to perform multi-protein analyses and use machine learning for image analysis of breast cancer tumors to understand more about tumor heterogeneity—i.e. differences between and within tumors—and how it affects risk and treatment benefit,” says Lindström.